Abstract
The clinical trial of isoproterenol (Isomenyl (R)), β-stimulant, on the peripheral vertigo was performed by the double blind technique. Diphenidol, which is recognized the effect on the vestibular vertigo, was used as active placebo. The subjects were 63 cases diagnosed peripheral vertigo, of which 7 cases were drop-outs and exculsion, and were divided into 3 groups (inner ear vertigo, Meniere's disease, others).
Total and each group were evaluated after 2 weeks administration. Isoproterenol on inner ear vertigo was statistically more effective against nausea and vomiting, and general improvement. Effects against other symptoms and signs were no significant difference between isoproterenol and diphenidol. Side effects of isoproterenol were few. These results show that isoproterenol is effective and safe on peripheral vertigo.
